NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee C) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 10 March 2021

**Location:** Via Zoom

# Committee members present

1. Professor Steve O’Brien [Chair] Present for all items
2. Dr Peter Selby [Vice Chair] Present for all items
3. Dr Alex Cale Present for all items
4. Michael Chambers Present for all items
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Natalie Hallas Present for all items
8. John Hampson Present for all items
9. Dr Nigel Langford Present for all items
10. Dr Andrea Manca Present for items 1 to 4.4.2
11. Iain McGowan Present for all items
12. Kirandip Moyo Present for items 1 to 3.4.2
13. Dr Mudasar Mushtaq Present for all items
14. Dr Richard Nicholas Present for all items
15. Ugochinyere Nwulu Present for all items
16. Stella O’Brien Present for all items
17. Professor Subhash Pokhrel Present for all items
18. Professor Andrew Renehan Present for all items
19. Professor Matthew Stevenson Present for items 1 to 3.4.2
20. Dr Paul Tappenden Present for all items

# NICE staff present:

Jasdeep Hayre, Associate Director Present for items 1 to 4.4.2

Ross Dent, Associate Director Present for items 5 to 5.4.2

Gavin Kenny, Project Manager Present for items 1 to 4.4.2

Louise Jafferally, Project Manager Present for all items

Victoria Kelly, Technical Adviser Present for items 1 to 3.4.2

Sally Doss, Technical Adviser Present for items 4 to 4.4.2

Alex Filby, Technical Adviser Present for items 5 to 5.4.2

Elizabeth Bell, Technical Analyst Present for items 1 to 3.4.2

Christian Griffiths, Technical Adviser Present for items 1 to 4.4.2

Thomas Keating, Technical Analyst Present for items 1 to 3.4.2

Ann Murray-Cota, Technical Analyst Present for items 1 to 3.4.2

Catherine Parker, Technical Analyst Present for items 1 to 3.4.2

Verena Wolfram, Technical Analyst Present for items 4 to 4.4.2

Ross Wilkinson, Assistant Technical Analyst Present for items 4 to 4.4.2

Anita Sanga, Technical Analyst Present for items 5 to 5.4.2

Gareth Murphy, Business Analyst Present for all items

Emilene Coventry, Medical Editor Present for items 1 to 3.4.2

Hayley Garnett, Medical Editor Present for items 4 to 4.4.2

Olivia Havercroft, Medical Editor Present for items 5 to 5.4.2

Setal Bachelard, Medical Editor Present for items 5 to 5.4.2

Emily Eaton Turner, Commercial & Managed Access Team Present for items 1 to 3.4.2 & 5 to 5.4.2

Ella Livingstone, Commercial & Managed Access Team Present for items 1 to 3.4.2

Thomas Strong, Commercial & Managed Access Team Present for items 4 to 4.4.2

Laura Marsden, Public Involvement Advisor, PIP Present for items 1 to 3.3 & 4 to 4.3

Mandy Tonkinson, Public Involvement Advisor, PIP Present for items 5 to 5.3

Catherine Pank, Assistant Project Manager, COT Present for items 4 to 4.4.2

Lucinda Evans, Coordinator, MIP Present for items 1 to 3.3 & 5 to 5.3

Rosalee Mason, Coordinator, MIP Present for items 4 to 4.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Present for items 1 to 4.4.2

Pratit Shah, Administrator, TA Present for items 5 to 5.4.2

Daniel Greenwood, Assistant Administrator, COT Present for items 5 to 5.4.2

Hollie Kemp, Apprentice, TA Present for items 1 to 3.3

# External group representatives present:

Jo Lord, Southampton Health Technology Assessment Centre, Present for items 1 to 3.3

Jonny Shepherd, Southampton Health Technology Assessment Centre, Present for items 1 to 3.3

Isaac Corro Ramos, Kleijnen Reviews Ltd, Present for items 4 to 4.3

Rob Riemsma, Kleijnen Reviews Ltd, Present for items 4 to 4.3

Professor Matt Stevenson, School of Health and Related Research, Present for items 5 to 5.3

Emma Simpson, School of Health and Related Research, Present for items 5 to 5.3

# Professional experts present:

Dr Sonia Craig, Consultant Sleep and Respiratory Physician, Liverpool University Hospitals NHS Foundation Trust, Present for items 1 to 3.3

Graham Hill, Chairman, Sleep Apnoea Trust Association, Present for items 1 to 3.3

Dr Ari Manuel, Consultant in Sleep Medicine, Liverpool University Trust, Present for items 1 to 3.3

Professor Adrian Williams, Consultant Physician, Queen Victoria Hospital & Guy’s and St Thomas, Present for items 1 to 3.3

Professor Peter Hillman, Professor of Experimental Haematology, University of Leeds, Present for items 4 to 4.3

Dr Austin Kulasekararaj, Consultant Haematologist and Lead for King’s National PNH service, King’s College Hospital NHS Foundation Trust, Present for items 4 to 4.3

Fiona Marley, Assistant Head of Specialised Commissioning, NHS England, Present for items 4 to 4.3

Alex Naylor, Patient expert nominated by The Aplastic Anaemia Trust, Present for items 4 to 4.3

Maria Piggin, Patient expert nominated by The Aplastic Anaemia Trust, Present for items 4 to 4.3

Ailsa Bosworth, Patient expert nominated by National Rheumatoid Arthritis Society, Present for items 5 to 5.3

Dr Frank McKenna, Consultant Physician and Rheumatologist, Manchester University Foundation Trust, Present for items 5 to 5.3

Teresa Shakespeare-Smith, Patient expert nominated by National Rheumatoid Arthritis Society, Present for items 5 to 5.3

Professor Peter Taylor, Norman Collisson Professor of Musculoskeletal Sciences & Head of Clinical Sciences, University of Oxford, Present for items 5 to 5.3

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None.
3. Appraisal of Solriamfetol for treating excessive waketime sleepiness caused by obstructive sleep apnoea [ID1499]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Jazz Pharmaceuticals.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Richard Nicholas declared a financial interest as he has attended paid advisory board for Novartis, Biogen, and Roche in the field of multiple sclerosis treatments.
* It was agreed that his declaration would not Richard from participating in this section of the meeting.
* Michael Chambers declared financial interests as he has provided consultancy advice to Shire Pharmaceuticals [manufacturer of a potential comparator therapy], in disease areas unrelated to this appraisal and most recently in late 2017. Shire is now part of Takeda Pharmaceuticals, with whom he currently has a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again unrelated to the topic of this appraisal
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Dr Prithwiraj Das declared a non-financial interest as he is employed as Head of Market Access, Respiratory and Immunology at AstraZeneca.
* It was agreed that his declaration would not prevent Prithwiraj from participating in this section of the meeting.
* Dr Sonya Craig declared a financial interest as she is currently sitting on an advisory board for Pitolisant which is another drug for excessive daytime sleepiness. She has declared this interest to the company making Solriamfetol and she says they were not concerned. She has also attended the ERS conference in Madrid 2019 paid for by Bioprojet who make Pitolisant. Sonya confirmed she had not received payment.
* It was agreed that her declaration would not prevent Sonya from providing expert advice to the committee.
* Dr Ari Manuel declared a financial interest as he carried out a lecture for Lincoln medical on the pathophysiology of OSA in April 2020 and was paid £400. He has also attended the International education meeting [USA/European based zoom] – where he talked on the need for more education in sleep medicine and was paid £1600.
* It was agreed that his declaration would not prevent Ari from providing expert advice to the committee.
* No further conflicts of interest were declared for this appraisal.
	1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Appraisal of Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Alexion.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Prithwiraj Das declared a non-financial interest as he is employed as Head of Market Access, Respiratory and Immunology at AstraZeneca.
* It was agreed that his declaration would not prevent Prithwiraj from participating in this section of the meeting.
* Dr Paul Tappenden declared a non-financial interest as he an unpaid member of a steering group on the NIHR-funded single arm SETSAhus study which is looking at the safety of withdrawing eculizumab treatment in atypical haemolytic uraemic syndrome. eculizumab is the comparator for the ravulizumab topic albeit in a different indication.
* It was agreed that his declaration would not prevent Paul from participating in this section of the meeting.
* Professor Peter Hillman declared a non-financial interest as he is the Chairman of the International PNH Interest Group [IPIG – the global organisation for professionals interested in PNH] and Trustee of the Aplastic Anaemia Trust [UK Charity for aplastic anaemia including PNH] he is also a Consultant in the UK National PNH Service
* It was agreed that his declaration would not prevent Peter from providing expert advice to the committee.
* Dr Austin Kulasekararaj declared a financial interest as he has attended advisory boards and received speaker’s bureau, travel grants and conference registration. He is also an investigator in clinical trials sponsored by Alexion.
* It was agreed that his declaration would not prevent Austin from providing expert advice to the committee.
* Alex Naylor declared a non-financial interest as she is a trustee for PNH Support.
* It was agreed that her declaration would not prevent Alex from providing expert advice to the committee.
* Committee member Professor Matt Stevenson declared pre meeting that he provided advice, for a fee, to Alexion at an early stage of their submission it was agreed this this was a direct conflict and prevented Matt from attending discussion on this appraisal.
* No further conflicts of interest were declared for this appraisal.
	1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2– Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Appraisal of Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed - partial review of TA375 [ID2710]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from AbbVie, Amgen, Biogen, Celltrion Healthcare, Fresenius Kabi, Pfizer, and Sandoz
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Richard Nicholas declared a financial interest as he has attended paid advisory board for Novartis, Biogen, and Roche in the field of multiple sclerosis treatments.
* It was agreed that his declaration would not Richard from participating in this section of the meeting.
* Michael Chambers declared financial interests as he recently been co-ordinating a training programme for Roche pharmaceuticals [manufacturer of a tocilizumab] in Real World Evidence, but this has not involved specific consideration of any Roche medicines.
* It was agreed that his declaration would not prevent Michael from participating in this section of the meeting.
* Dr Prithwiraj Das declared a non-financial interest as he is employed as Head of Market Access, Respiratory and Immunology at AstraZeneca.
* It was agreed that his declaration would not prevent Prithwiraj from participating in this section of the meeting.
* Dr Paul Tappenden declared a non-financial interest as he is employed by ScHARR [AG for this appraisal]. Paul confirmed he has not been involved in the production or peer review of the ERG report.
* It was agreed that his declaration would not prevent Paul from participating in this section of the meeting.
* Ailsa Bosworth declared a financial interest as NRAS has received educational grants in the last 12 months from some of the companies involved in this MTA review.
* It was agreed that her declaration would not prevent Ailsa from providing expert advice to the committee.
* Dr Frank McKenna declared a financial interest as he is receipt of an honorarium from Biogen in December 2019 for giving a lecture to non-medical prescribers on NICE guidelines and guidance in Rheumatology and Gastroenterology. The meeting was funded by Biogen.
* It was agreed that his declaration would not prevent Frank from providing expert advice to the committee.
* Professor Peter Taylor declared a financial interest as his PCT has received consultation fees from AbbVie, BMS, Biogen, Janssen, Pfizer, Roche, Fresenius and UCB and he is Chief medical advisor to NRAS.
* It was agreed that his declaration would not prevent Peter from providing expert advice to the committee.
* No further conflicts of interest were declared for this apprasal.
	1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Tuesday 13 April 2021 and will start promptly at 09.30am.